KGbio
Christoffer Aryanto is a BD&L Associate at KGbio since September 2023. Christoffer previously worked as a Data Analyst at PT Kalbe Farma, Tbk, a Business Development Consultant at noDokter, and a Product Development Consultant at PT Bintang Toedjoe. Christoffer also has experience as a Research Assistant at the Stem Cell and Cancer Institute. Christoffer holds a Bachelor of Science in Molecular Environmental Biology with a Minor in Data Science from the University of California, Berkeley.
This person is not in any offices
KGbio
KGbio is a clinical-stage biotechnology company focused on bringing biologics medical innovation to markets outside the US/Canada, Western Europe and China. The business model revolves around in-licensing novel biologics and select biosimilars in oncology and high-specialty therapeutic areas (typically pre-IND or early clinical stage), with the objective to out-license them in target geographies after finishing clinical development as well as regulatory and reimbursement approvals. Platforms of interest currently include Fc-fusion proteins, antibodies, bispecifics, ADCs, cell therapies and therapeutic vaccines. The company is backed by Asian pharma companies Kalbe (market cap US$5.5 billion) and Genexine (market cap US$1.3 billion) and US private equity giant General Atlantic (AUM US$ 78 billion).